Patients with CA125 < 35 IU/mL, HE4 ≥ 142 pmol/L, and with an observed tumour invasion of ≥1⁄2 of the myometrium, uterine serosal invasion, or cervical stromal invasion, were classified as high-risk. This evidence concerns the gene MUC16 and neoplasm.